drugset / Trial / NCT01343966
A Study to Evaluate the Efficacy and Safety of MABT5102A in Patients With Mild to Moderate Alzheimer's Disease (ABBY)
RandomizedParallel-groupDouble-blindTreatment
Summary
This is a Phase II, randomized, double-blind, parallel-group, placebo-controlled study to evaluate the safety and efficacy of MABT5102A in patients with mild to moderate Alzheimer's Disease.
Timeline
- Start
- 2011-04-30
- Primary completion
- 2014-02-28
- Completion
- 2014-02-28
Publications
- Polhamus DG, Dolton MJ, Rogers JA, Honigberg L, Jin JY, Quartino A. Longitudinal Exposure-Response Modeling of Multiple Indicators of Alzheimer's Disease Progression. J Prev Alzheimers Dis. 2023;10(2):212-222. doi: 10.14283/jpad.2023.13.
- Yoshida K, Moein A, Bittner T, Ostrowitzki S, Lin H, Honigberg L, Jin JY, Quartino A. Pharmacokinetics and pharmacodynamic effect of crenezumab on plasma and cerebrospinal fluid beta-amyloid in patients with mild-to-moderate Alzheimer's disease. Alzheimers Res Ther. 2020 Jan 22;12(1):16. doi: 10.1186/s13195-020-0580-2.
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Crenezumab | Monoclonal antibody | 15 mg/kg | Subcutaneous |
| Subject | Crenezumab | Monoclonal antibody | 30 mg/kg | Subcutaneous |
| Subject | Crenezumab | Monoclonal antibody | 45 mg/kg | Subcutaneous |
| Subject | Crenezumab | Monoclonal antibody | 60 mg/kg | Subcutaneous |
| Subject | Crenezumab | Monoclonal antibody | 120 mg/kg | Subcutaneous |
| Subject | Crenezumab | Monoclonal antibody | 300 mg | Subcutaneous |